455 related articles for article (PubMed ID: 16583545)
1. [Drug development costs are overstated by the industry].
Jeppsson A
Lakartidningen; 2006 Mar 1-7; 103(9):663-4; discussion 664. PubMed ID: 16583545
[No Abstract] [Full Text] [Related]
2. Pharmaceutical research: cost savings through innovation.
Cohen KR; Levy RA
AAPPO J; 1993 Oct; 3(5):28-36. PubMed ID: 10146463
[No Abstract] [Full Text] [Related]
3. Drug costs: research and development costs: the great illusion.
Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226
[TBL] [Abstract][Full Text] [Related]
4. Industry-sponsored pharmaceutical trials and research ethics boards: are they cloaked in too much secrecy?
Ferris LE
CMAJ; 2002 May; 166(10):1279-80. PubMed ID: 12041844
[No Abstract] [Full Text] [Related]
5. [The roles and responsibilities of the pharmaceutical industry].
Dejgaard A; Thomsen MK
Ugeskr Laeger; 2003 Apr; 165(16):1676-9. PubMed ID: 12756829
[TBL] [Abstract][Full Text] [Related]
6. The state of innovation in drug development.
Kola I
Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
[TBL] [Abstract][Full Text] [Related]
7. The price of pills. Does it really take $897 million for a new therapy?
Ezzell C
Sci Am; 2003 Jul; 289(1):25. PubMed ID: 12840941
[No Abstract] [Full Text] [Related]
8. Two ideas to increase innovation and reduce pharmaceutical costs and prices.
Jayadev A; Stiglitz J
Health Aff (Millwood); 2009; 28(1):w165-8. PubMed ID: 19088104
[TBL] [Abstract][Full Text] [Related]
9. [Is society going to finance projects of drug companies?].
Bake B
Lakartidningen; 1999 May; 96(19):2327-8. PubMed ID: 10377674
[No Abstract] [Full Text] [Related]
10. [Current challenges for the pharmaceutical research industry].
Chalchat B
Ann Pharm Fr; 1993; 51(1):16-25. PubMed ID: 8215118
[TBL] [Abstract][Full Text] [Related]
11. The pharmaceutical industry--to whom is it accountable?
Hayes TA
N Engl J Med; 2000 Nov; 343(19):1416; discussion 1417. PubMed ID: 11183881
[No Abstract] [Full Text] [Related]
12. Fewer new drugs from the pharmaceutical industry.
Taylor D
BMJ; 2003 Feb; 326(7386):408-9. PubMed ID: 12595352
[No Abstract] [Full Text] [Related]
13. Industry sponsored bias in cost effectiveness analyses.
John-Baptiste A; Bell C
BMJ; 2010 Oct; 341():c5350. PubMed ID: 20943724
[No Abstract] [Full Text] [Related]
14. Costing drug development.
Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
[No Abstract] [Full Text] [Related]
15. Drug price deal spells windfall for researchers.
Bosch X
Nature; 2001 Nov; 414(6860):138. PubMed ID: 11700514
[No Abstract] [Full Text] [Related]
16. Victoria, a springboard for a research based pharmaceutical industry.
Windle HK
Australas Biotechnol; 1991 Oct; 1(2):88-91. PubMed ID: 1367647
[No Abstract] [Full Text] [Related]
17. Cutting the cost of drug development?
Rawlins MD
Nat Rev Drug Discov; 2004 Apr; 3(4):360-4. PubMed ID: 15060531
[No Abstract] [Full Text] [Related]
18. [Pharmaceutical industry and clinical drug research].
Huttunen MO
Duodecim; 2000; 116(24):2813-5. PubMed ID: 12077886
[No Abstract] [Full Text] [Related]
19. [Dishonesty in clinical trials is expensive for the society 3].
Waldorff S
Ugeskr Laeger; 2003 Jun; 165(26):2672-3; author reply 2673-4. PubMed ID: 12886557
[No Abstract] [Full Text] [Related]
20. [Dishonesty in clinical trials is expensive for the society 2].
Lund BA; Nordby G
Ugeskr Laeger; 2003 Jun; 165(26):2672. PubMed ID: 12886556
[No Abstract] [Full Text] [Related]
[Next] [New Search]
